| |
|
Product Name:
|
A1998/3-2
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Virus Classification: Pneumoviridae, Orthopneumovirus
Species: Human Respiratory Syncytial Virus
Strain: A1998/3-2
|
|
Additional Information:
|
RSV was first isolated from infants in 1957 and is recognized as the primary cause of hospitalization for lower respiratory tract illnesses among infants and young children worldwide.5,6 RSV has a negative-sense RNA genome encoding for 10 proteins, of which 2 are nonstructural.6 RSV envelope glycoprotein (G protein) is integral to the immunity and pathogenesis of the virus, and depending on its sequence variation, RSV is divided into two groups, A and B.6,7
|
|
Material Provided:
|
Each vial contains approximately 1 mL of cell lysate and supernatant from Homo sapiens epithelial carcinoma cells (HEp-2; ATCC® CCL-23™) infected with RSV, A1998/3-2.
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-28529 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Host: Homo sapiens epithelial carcinoma cells (HEp-2; ATCC® CCL-23™)
Growth Medium: Dulbecco’s Modified Eagle’s Medium modified to contain 4 mM L-glutamine, 4500 mg per L glucose, 1 mM sodium pyruvate and 1500 mg per L of sodium bicarbonate supplemented with 2% fetal bovine serum, or equivalent
Infection: Cells should be approximately 80 to 90% confluent
Incubation: 5 to 11 days at 37°C and 5% CO2
Cytopathic Effect: Cell rounding and syncytia formation
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Moore, M. L., Personal Communication.
2. Stokes, K. L., et al. “Differential Pathogenesis of Respiratory Syncytial Virus Clinical Isolates in BALB/c Mice.” J. Virol. 85 (2011): 5782-5793. PubMed: 21471228.
3. Nakanishi, A., et al. “Role of gob-5 in Mucus Overproduction and Airway Hyperresponsiveness in Asthma.” Proc. Natl. Acad. Sci. USA 98 (2001): 5175-5180. PubMed: 11296262.
4. Walter, D. M., et al. “Critical Role for IL-13 in the Development of Allergen-Induced Airway Hyperactivity.” J. Immunol. 167 (2001): 4668-4675. PubMed: 11591797.
5. Hall, C. B. “The Burgeoning Burden of Respiratory Syncytial Virus Among Children.” Infect. Discord. Drug Targets 12 (2012): 92-97. PubMed: 22335498.
6. Hall, C. B. “Respiratory Syncytial Virus and Parainfluenza Virus.” N. Engl. J. Med. 344 (2001): 1917-1928. PubMed: 11419430.
7. Howard, T. S., et al. “Respiratory Syncytial Virus Pneumonia in the Hospital Setting: Length of Stay, Charges, and Mortality.” J. Pediatr. 137 (2000): 227-232. PubMed: 10931416.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was contributed by Division of Viral Diseases, Centers for Disease Control and Prevention for distribution through BEI Resources, NIAID, NIH: Human Respiratory Syncytial Virus, A1998/3-2, NR-28529."
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|